QUAD shot方案对晚期头颈部鳞癌的疗效:多中心前瞻性观察研究
日本放射肿瘤学研究组18-2多中心前瞻性观察研究评估QUAD shot方案(每周期14–14.8 Gy分4次、连续2天,最多3周期)对III–IV期头颈部鳞癌的姑息疗效,48例可分析患者中81%完成3周期,88%体检确认治疗反应,3–4级毒性低,QOL稳定或改善,中位OS 8.3个月。
要点
- 48例可分析患者中81%完成全部3周期,88%体检确认治疗反应。
- 3级和4级放疗相关毒性分别见于4例(8%)和1例(2%)。
- T分期<T4及完成3周期与OS和PFS改善显著相关。
核心结论
- QUAD shot方案采用3D-CRT或IMRT可达高3周期完成率、良好姑息效果、较低毒性及稳定或改善的QOL。
- 推荐完成3周期以改善治疗结局。
研究设计与样本
- 多中心前瞻性观察研究纳入50例III–IV期头颈部鳞癌患者,48例纳入分析。
- 每周期14–14.8 Gy分4次、连续2天给药,最多重复3周期。
- 采用3D-CRT者16例(33%),IMRT者32例(67%)。
主要发现
- 放疗相关3级和4级毒性分别见于4例(8%)和1例(2%)。
- 3个月时12个领域特异性QOL评分中超过50%患者报告相同或更好状态,全局QOL超过70%报告相同或更好、3个月时升至超过80%。
- 中位总生存8.3个月,中位无进展生存6.7个月。
- 多因素分析显示T分期<T4与OS改善显著相关(P=.001)、与PFS改善显著相关(P=.026);完成3周期与OS改善显著相关(P=.004)、与PFS改善显著相关(P=.014)。
关键数值与推荐
- 每周期剂量14–14.8 Gy分4次、连续2天,最多3周期。
- T分期<T4者OS(P=.001)和PFS(P=.026)改善显著相关。
- 完成3周期者OS(P=.004)和PFS(P=.014)改善显著相关。
临床怎么用
- 对晚期头颈部鳞癌可采用QUAD shot方案行姑息放疗,3D-CRT或IMRT均可。
- 优先完成3周期以争取更好的生存结局。
- T分期<T4患者可能从该方案获得更优生存获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The palliative effects of the QUAD shot regimen were prospectively assessed using 3-dimensional conformal radiation therapy (3D-CRT) or intensity modulated radiation therapy (IMRT) for advanced head and neck squamous cell carcinoma. METHODS AND MATERIALS: Fifty patients with stage III to IV head and neck squamous cell carcinoma were enrolled. One cycle consisted of 14 to 14.8 Gy in 4 fractions administered over 2 consecutive days and was repeated up to 3 cycles. Toxicity and quality of life (QOL) were assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0, and the University of Washington QOL Questionnaire, version 4, respectively. RESULTS: Two patients refused treatment prior to the initial cycle, whereas the remaining 48 were included in the analysis. 3D-CRT and IMRT were delivered to 16 (33%) and 32 (67%) patients, respectively. Thirty-nine (81%) patients completed all 3 cycles. Treatment response on physical examination was confirmed in 42 (88%) patients. Radiation therapy-associated grade 3 and 4 toxicities were observed in 4 (8%) and 1 (2%) patients, respectively. Of the 12 domain-specific QOL scores, >50% of patients reported the same or better status across all domains at 3 months. The global QOL scores were well preserved, with >70% of patients reporting the same or better scores, rising to >80% at 3 months. The median overall survival was 8.3 months. Multivariate analysis indicated that a T category < T4 (P = .001) and 3 QUAD shot cycles (P = .004) were significantly associated with improved overall survival. The median progression-free survival was 6.7 months. Multivariate analysis indicated that a T category < T4 (P = .026) and 3 QUAD shot cycles (P = .014) were significantly associated with improved progression-free survival. CONCLUSIONS: The QUAD shot regimen using 3D-CRT or IMRT achieves a high completion rate over 3 cycles, good palliative effects with lower toxicity, and improved or stable QOL. Three cycles are preferred for improved treatment outcomes.
引用
- Toya R, Kodaira T, Tamaki Y, et al. Effectiveness of the QUAD Shot Regimen for Advanced Head and Neck Squamous Cell Carcinoma: A Multicenter Prospective Observational Study (Japanese Radiation Oncology Study Group 18-2). Pract Radiat Oncol. 2026. PMID: 41974367. doi:10.1016/j.prro.2026.03.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。